# Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

> **NCT01103414** · PHASE2 · COMPLETED · sponsor: **Metabolic Solutions Development Company** · enrollment: 356 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Mitoglitazone
- **DRUG:** Mitoglitazone
- **DRUG:** Mitoglitazone
- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01103414
- **Lead sponsor:** Metabolic Solutions Development Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103414, "Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01103414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*